pubrio
Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

Public
alnylam.com
生物技術研究2,600+ employeesFounded 2002🇺🇸 美國

SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."

成立年份
2002
員工
2,600+
行業
生物技術研究
公司類型
Public Company
股票
nasdaq: ALNY
總部
🇺🇸Cambridge, Massachusetts (+8)
專長
研究產業製藥產業生物技術醫療保健生物技術研究
5 / 11
活躍市場
2
新市場
FR · IN
信心度
大多為早期訊號
0%
動能
對比上一週期
33 / 100
擴張評分
發展中
階段1探索中10投入中
6 個訊號 · 過去 90 日

全球擴張

即時
GBDECH
階段
探索中投入中進入中營運中
+8個市場已鎖定
已顯示 11 個中的 3 個

解鎖市場時間軸與訊號動態

活動脈搏

過去 90 日內有 6 個訊號。

過去 90 日
招聘
6↑ +100%
招聘
市場推廣與公關
0
無活動
產品與技術
0
無活動
+2個類別已鎖定
已顯示 5 個中的 3 個

市場進入時間軸

此公司進入各市場的次序 — 由最舊至最新

1
🇬🇧GB第 1st 個進入的市場 · 2022推進中
投入中
24 個訊號投入中 階段
2
🇩🇪DE第 2nd 個進入的市場 · 2024推進中
投入中
21 個訊號投入中 階段
3
🇨🇭CH第 3rd 個進入的市場 · 2025推進中
投入中
11 個訊號投入中 階段
+8個市場已鎖定
已顯示 11 個中的 3 個
目前階段投入中投入資源
信心度35%
開始追蹤於2022首個訊號

近期訊號

招聘🇮🇹 IT2星期前

Sr Manager, Medical Science Liaison - LOMBARDIA EST / TRIVENETO

招聘🇨🇭 CH上個月

Director, Medical Affairs

註冊以查看完整訊號動態

值得了解

關於 Alnylam Pharmaceuticals 的常見問題

關於 Alnylam Pharmaceuticals 業務、市場及增長訊號的快速解答。

SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."

立即展開你的旅程

可以先用平台,也可以先聊聊

自行使用 Pubrio,或讓我們的團隊協助研究、挖掘潛在客戶,甚至串接資料。

Start Journey Image
pubrio

Pubrio 將 50+ 個在地來源的商業、人才與意圖數據全球化整合,讓 AI 與營收團隊掌握完整市場視野。

© 2026 Pubrio。版權所有。